Serum Carcinoembryonic Antigen (CEA) and Tumor Characteristics Correlate with UBE2Q1 Protein Expression in Colorectal Cancer Patients
Abstract
Objectives: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, ranking third in men and second in women. The ubiquitin-conjugating enzyme UBE2Q1 has been reported to be overexpressed in colorectal tumors, yet its role in CRC pathogenesis and prognosis remains unclear. Carcinoembryonic antigen (CEA) is a well-established biomarker elevated in CRC, used to monitor treatment response and disease progression. This study aimed to investigate the association between UBE2Q1 gene expression and CRC prognosis by evaluating its correlation with serum CEA levels.
Methods: In this cross-sectional study, 48 CRC patients undergoing surgery at Faghihi Hospital, Shiraz University of Medical Sciences, were analyzed. Tumor and adjacent normal tissues were collected for UBE2Q1 expression analysis via Western blotting. Concurrently, serum CEA concentrations were measured using ELISA and liver function tests were measured by Auto analyzer. Clinical and pathological data, including tumor size, lymph node involvement, and liver function tests, were also recorded.
Results: The cohort had a mean age of 57.2 ± 14.6 years, with equal gender distribution. Mean serum CEA was 2.35 ± 3.45 ng/mL, and UBE2Q1 expression was 5.80 ± 12.39 arbitrary units. Tumor size averaged 29.17 ± 46.13 cm²; 21.4% had lymph node metastasis, and 70% exhibited well-differentiated pathology. Tumors were predominantly located in the rectum (35.7%) and colon (33.3%). A significant positive correlation was observed between serum CEA levels and UBE2Q1 expression (Spearman’s ρ = 0.38, p < 0.05). UBE2Q1 expression also correlated significantly with alkaline phosphatase and AST liver enzymes (p < 0.05). No significant associations were found between UBE2Q1 expression and age, sex, or histopathological features, while serum CEA correlated with pathological differentiation.
Conclusion: UBE2Q1 protein expression is positively associated with serum CEA levels and certain liver function markers, suggesting its potential utility as a prognostic biomarker in CRC. Further studies are warranted to elucidate its mechanistic role and clinical applicability.
2. Rohani-Rasaf M, Abdollahi M, Jazayeri S, Kalantari N, Asadi-Lari M. Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev. 2013;14(3):1669-76. https://doi.org/10.7314/apjcp.2013.14.3.1669
3. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterol. 2010;138(2):487-92. https://doi.org/10.1053/j.gastro.2009.10.051
4. van Lier MG, Leenen CH, Wagner A, Ramsoekh D, Dubbink HJ, van den Ouweland AM, et al. Yield of routine molecular analyses in colorectal cancer patients 5. Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol. 2015;12(2):88-97. https://doi.org/10.1038/nrgastro.2014.229
6. Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology. 2014;147(2):418-29 e8. https://doi.org/10.1053/j.gastro.2014.04.039
7. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol. 2011;29(10):1382-91. https://doi.org/10.1200/JCO.2010.28.2319
8. Group ECCSGW. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(01):51-9. https://doi.org/10.1055/s-0032-1325997
9. van Heijningen EM, Lansdorp-Vogelaar I, Kuipers EJ, Dekker E, Lesterhuis W, Ter Borg F, et al. Features of adenoma and colonoscopy associated with recurrent colorectal neoplasia based on a large community-based study. Gastroenterol. 2013;144(7):1410-8. https://doi.org/10.1053/j.gastro.2013.03.002
10. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513-22. https://doi.org/10.1002/ijc.28384
11. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234(4774):364-8. https://doi.org/10.1126/science.2876518
12. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 2009;100(1):24-8. https://doi.org/10.1111/j.1349-7006.2008.01013.x
13. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235-7. https://doi.org/10.1038/359235a0
14. Voutsadakis IA. The ubiquitin-proteasome system in colorectal cancer. Biochim Biophys Acta. 2008;1782(12):800-8. https://doi.org/10.1016/j.bbadis.2008.06.007
15. Yu H, Matouschek A. Recognition of Client Proteins by the Proteasome. Annu Rev Biophys. 2017;46(1):149-73. https://doi.org/10.1146/annurev-biophys-070816-033719
16. Hjerpe R, Bett JS, Keuss MJ, Solovyova A, McWilliams TG, Johnson C, et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. 2016;166(4):935-49. https://doi.org/10.1016/j.cell.2016.07.001
17. Bustamante HA, González AE, Cerda-Troncoso C, Shaughnessy R, Otth C, Soza A, et al. Interplay between the autophagy-lysosomal pathway and the ubiquitin-proteasome system: a target for therapeutic development in Alzheimer’s disease. Front Cell Neurosci. 2018;12:126. https://doi.org/10.3389/fncel.2018.00126
18. Seghatoleslam A, Monabati A, Bozorg-Ghalati F, Nikseresht M, Bordbar MR, Rahvar M, et al. Expression of UBE2Q2, a putative member of the ubiquitin-conjugating enzyme family in pediatric acute lymphoblastic leukemia. Arch Iran Med. 2012;15(6):352-5.
19. Seghatoleslam A, Nikseresht M, Shafiee SM, Monabati A, Namavari MM, Talei A, et al. Expression of the novel human gene, UBE2Q1, in breast tumors. Mol Biol Rep. 2012;39(5):5135-41. https://doi.org/10.1007/s11033-011-1309-x
20. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010;17(1):86-92. https://doi.org/10.1038/cdd.2009.77
21. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6(1):479-507. https://doi.org/10.1146/annurev-pathol-011110-130235
22. McBride O, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). PNAS. 1986;83(1):130-4. https://doi.org/10.1073/pnas.83.1.130
23. Chang R, Wei L, Lu Y, Cui X, Lu C, Liu L, et al. Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma. J Mol Histol. 2015;46:45-56. https://doi.org/10.1007/s10735-014-9596-x
24. Shafiee SM, Seghatoleslam A, Nikseresht M, Hosseini SV, Alizadeh-Naeeni M, Safaei A, et al. UBE2Q1 expression in human colorectal tumors and cell lines. Mol Biol Rep. 2013;40(12):7045-51. https://doi.org/10.1007/s11033-013-2824-8
25. Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, et al. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathway. Mol Carcinog. 2018;57(2):201-15. https://doi.org/10.1002/mc.22747
26. Topno R, Singh I, Kumar M, Agarwal P. Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer. BMC cancer. 2021;21:1-13. https://doi.org/10.1186/s12885-021-07928-z
27. Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer. 1988;41(2):287-96. https://doi.org/10.1002/ijc.2910410221
28. Jeon BG, Shin R, Chung JK, Jung IM, Heo SC. Individualized cutoff value of the preoperative carcinoembryonic antigen level is necessary for optimal use as a prognostic marker. Ann Coloproctol 2013;29(3):106. https://doi.org/10.3393/ac.2013.29.3.106
29. Wu S, Gu W. Association of T Stage and Serum CEA Levels in Determining Survival of Rectal Cancer. Front Med (Lausanne). 2019;6:270. https://doi.org/10.3389/fmed.2019.00270
30. Siregar GA, Sibarani H. Comparison of carcinoembryonic antigen levels among degree of differentiation and colorectal cancer’s location in medan. Open Access Maced J Med Sci. 2019;7(20):3447. https://doi.org/10.3889/oamjms.2019.442
31. Li M, Li JY, Zhao AL, He JS, Zhou LX, Li YA, et al. Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer. Colorectal Dis. 2009;11(3):276-81. https://doi.org/10.1111/j.1463-1318.2008.01591.x
| Files | ||
| Issue | Vol 2 No 4 (2024) | |
| Section | Original Articles | |
| Keywords | ||
| Colorectal Neoplasms Carcinoembryonic Antigen Ubiquitin Conjugating Enzyme E2 Q Pathology | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
